Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.
Key catalysts approach for Orphazyme, Gemini and Immutep.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
Full data on Lilly's Alzheimer’s antibody will disappoint some, and point to a long road ahead.
Expectations are high ahead of a detailed look at donanemab data, but hopes for a fast path to market feel overblown.